EMA's SME Office Highlights Positive Drug Approval Trends
By Nuala Moran
Tuesday, February 26, 2013
LONDON Biotechs registered with the SME (small- and medium-sized enterprise) Office of the European Medicines Agency (EMA) have seen consistent improvements in the success rate of applications for marketing approvals, according to a report analyzing activity in the seven years since the office was set up in 2005.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.